Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, founded in 2003, is a biopharmaceutical company operating within the Healthcare and Pharmaceuticals sectors. The company specializes in developing medicines that target intractable diseases by silencing the genes responsible for their causation. Their core technology leverages RNA interference (RNAi), a natural cellular mechanism that inhibits gene expression, thereby controlling protein production. This innovative approach aims to induce rapid, deep, and durable knockdown of target genes, offering novel therapeutic pathways.

With a workforce of 500-1,000 employees and operations spanning 4 locations, Arrowhead Pharmaceuticals is dedicated to advancing its pipeline of RNAi-based therapeutics. The company's product development focuses on harnessing the power of RNAi to address a range of conditions. Their clinical-stage pipeline includes investigational medicines designed for various diseases. Understanding the team behind these advancements is crucial; Meet Arrowhead Pharmaceuticals's team to learn more about the leadership and expertise driving their research and development efforts.

Arrowhead Pharmaceuticals reported a revenue of $622.0M. The company has also secured significant funding, including a recent $500 million debt financing round from Sixth Street in August 2024, underscoring investor confidence in their long-term strategy. They operate in a competitive landscape with companies like Dicerna, Blueprint Medicines, and Lantheus. For a detailed look at their financial performance and strategic investments, Explore financial highlights. Their commitment to developing transformative treatments positions them as a key player in the biopharmaceutical industry.